Cardinal Health recently approved an increase in its quarterly dividend, a move that aligns with the company's notable 21% price increase last quarter. This uptick came despite a general market decline as investors awaited updates on tariffs and the Federal Reserve's decisions. The company's quarterly earnings announcements revealed substantial growth, with net income nearly doubling year over year, which may have buoyed investor sentiment. Additionally, Cardinal Health's partnership with Telix Pharmaceuticals and their ongoing share buyback program might have further bolstered confidence in the company during a period when many stocks experienced volatility and minor declines. We've spotted 1 weakness for Cardinal Health you should be aware of.NYSE:CAH Revenue & Expenses Breakdown as at May 2025 Uncover 15 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent dividend increase approved by Cardinal Health aligns with its ongoing share buyback program, likely reinforcing investor confidence amid market volatility. Over the last five years, Cardinal Health's total shareholder return, which includes both share price appreciation and dividends, surged by 228.65%. This significant long-term performance stands in strong contrast with the one-year return, where the company outperformed the broader US Healthcare industry, which saw a 10% decline. Investors appear optimistic about Cardinal Health's strategic acquisitions and their potential impact on revenue and earnings growth. The integration of GI Alliance and ION could expand therapeutic offerings, aligning with analyst forecasts of continued revenue and profit margin enhancement. Although current analyst projections set a price target at US$143.74, just 2.7% above the current price of US$139.84, this suggests analysts view the shares as fairly priced based on expected performance improvements. Assess Cardinal Health's previous results with our detailed historical performance reports. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Story Continues Companies discussed in this article include NYSE:CAH. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected] View Comments
Cardinal Health (NYSE:CAH) Announces Dividend Increase to US$1 Per Share
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...